title: Study on the efficacy and safety of Xueyou Mixture in treating hemophilia.
abstract: OBJECTIVE
  To observe the effect of Xueyou Mixture (, XYM) on blood coagulation factors and its safety in treating hemophilia.
  
  
  METHODS
  To the randomly selected 65 inpatients of hemophilia, XYM was administered accompanied with intravenous dripping of liver cell growth factor 60-100 mg once a day to protect the liver, with no blood products like concentrated VIII and FIX factors or blood plasma given. The treatment lasted for 3 weeks. The short-term efficacy and adverse reactions were observed. The long-term efficacy in patients was observed in a follow-up study of 6-12 months after they were discharged from the hospital but continuously took XYM orally.
  
  
  RESULTS
  The short-term markedly effective rate in the patients was 95.38% (62/65). After they were treated for 3 weeks, the level of FVIII factor activity increased in 56 patients of type A from (3.32+/-2.21) % to (4.18+/-2.23) %, and in 9 of type B from (4.92+/-1.81) % to (5.64+/-1.96) %. Compared with that before treatment, the difference was significant in both of them (P<0.01). No obvious adverse reaction was found in the treatment period. The follow-up study showed that in 22 patients of type A, the FVIII factor activity ratio increased from (3.25+/-2.11) % to (6.31+/-2.16) %, (8.36+/-1.05) %, and (16.38+/-2.71) % in the 2nd, 3rd and 6th month after discharge respectively, all showing significant difference to that before treatment (P<0.01); and in 4 patients of type B, it increased from (4.15+/-2.26) % to 7.8% and 11.6% (mean value) in the 2nd and 6th month respectively.
  
  
  CONCLUSIONS
  XYM could raise the activity of factors VIII and IX in patients with hemophilia, and the degree of the rise is related with the duration of the therapy, with no obvious adverse reaction, which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.
authors.affiliation: Shanxi YiDa Institute of Hematopathy, Xi'an, 710061, China. www.yyy.cc@163.com
authors.forename: Shan-xi
authors.initials: SX
authors.lastname: Liu
authors.forename: Lin
authors.initials: L
authors.lastname: Jiang
authors.forename: Yi-guo
authors.initials: YG
authors.lastname: Liu
authors.forename: Yue-qin
authors.initials: YQ
authors.lastname: He
authors.forename: Xin
authors.initials: X
authors.lastname: Liang
authors.forename: Wei-wei
authors.initials: WW
authors.lastname: Kong
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged
chemical_list: D001779:Blood Coagulation Factors; D004365:Drugs, Chinese Herbal; D006454:Hemoglobins